Introduction
Malignant otitis externa (MOE), or skull base osteomyelitis, was first described by Chandler 1 in 1968. It is a progressive, potentially life-threatening infection of the temporal bone that can spread to other areas of the skull base. The most common causative agent remains Pseudomonas aeruginosa, but other species of bacteria, including methicillinresistant Staphylococcus Aureus (MRSA), as well as fungal species have been reported. [2] [3] [4] [5] Malignant otitis externa is known to have a predilection for elderly, diabetic, and/or immunocompromised patients. 6 Common presenting symptoms of MOE include otalgia, otorrhea, aural fullness, and hearing loss. Many of the symptoms of otitis externa are also common to MOE, which can make diagnosis difficult and may lead to a delay in escalating treatment. More advanced cases of MOE may present with cranial neuropathies, including facial nerve palsy in 17% to 26% of cases. 7, 8 Involvement of cranial nerves is an ominous sign that is associated with higher rates of mortality. 9 Patients often require admission for IV antibiotics and medical management of their underlying comorbidities.
Methods
The UHC is an organization that delivers approximately 30% of inpatient medical care in the US, including most US academic medical centers. 11 The UHC maintains a data repository, which compiles inpatient discharge summaries, among other measures of medical care. This de-identified data may be accessed online via the UHC Clinical Database/Resource Manager (CDB/RM) and exported in summary format that composites patient groups based on the search query (individual patient-level data were unavailable). This study was deemed exempt by our Institutional Review Board.
The UHC CDB/RM was accessed in June 2016 for inpatient discharges over a 36-month time span (October 2012 -September 2015 . Patients diagnosed with MOE were identified by the corresponding ICD-9-CM diagnosis code (380.14).
Patients were categorized into 6 age groups (<18 years, 18-30 years, 31-50 years, 51-64 years, 65-74 years, 75-84 years, and >84 years). Some age groups were combined from the UHC database as their subgroups had a small number of cases, and we believe these groups to be homogenous. Patients were also categorized into groups by payer type, including private insurance, self-pay, state-funded insurance (Medicaid), or federally funded insurance (Medicare). Smaller groups such as charity, military, other, and incarcerated were combined into 1 category. The patients were also categorized by race, including Caucasian, African American, Asian, or other. The patients that were identified as other were excluded from the statistical analysis regarding race.
Two distinct patient characteristics were analyzed: comorbidities and acute complications. Comorbidities are defined as medical conditions or disorders that the patient had upon admission and were documented using the ICD-9 coding system. These comorbidities were predefined by Elixhauser Comorbidity Software for ICD-9-CM, a categorization scheme for certain comorbidities associated with substantial increases in length of stay (LOS) and mortality. 12 For example, this software assigns "diabetes with chronic complications" to diabetic patients with complications including neuropathy, vasculopathy, and retinopathy, while the remaining patients were assigned "diabetes without chronic complications."
Conversely, acute complications developed during hospitalization are tracked in the database. Acute complications are assigned by the database when cases meet any of the criteria set by the reportable complication metrics developed by the Agency for Healthcare Research and Quality, UHC, or Centers for Medicare & Medicaid. The UHCtracked acute complications include generalized complications such as stroke, aspiration, and respiratory failure and do not include specific outcomes typically associated with MOE (eg, facial nerve paralysis).
Readmissions rates were also included in statistical analysis. Readmissions are defined by the UHC database as the readmission diagnosis was the same as the original diagnosis within a 30-day period. Mean and standard deviations were calculated for LOS, and means were calculated for intensive care unit (ICU) LOS. 
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Results
We identified 786 cases of MOE that were treated at 187 hospitals during the 36-month time span (Table 1 ). The mean LOS was 18.6 ± 19.7 days. There were 73 (9.3%) patients admitted to the ICU with a mean ICU LOS of 6.8 days. The overall complication rate was 4.3%, and the mortality rate was 2.5%. The most common acute complications were stroke, Clostridium difficile enteritis, readmission due to infection, aspiration, and myocardial infarction. There were 27 (3.4%) patients who required readmission within 30 days after discharge for reasons related to MOE.
Age
Advancing age correlated with an increased mortality rate (r = 0.955; 95% CI, 0.95-0.97) ranging from 0% in patients 30 years and younger to 4.3% in patients 85 years and older. Readmission rates declined with age, having a strong correlation (r = −0.95; 95% CI, −0.96 to 0.94). The less than 18 age group had the highest readmission rate of 15.9%, while the oldest age group (>84) had zero readmissions. There were no significant differences with respect to LOS and complication rate among age groups. 
Race
There were no statistically significant differences in the mean LOS based on race (Caucasians 7. There was a significant difference between groups in prevalence of diabetes with associated chronic comorbidities (ES = 0.28; 95% CI, 0.12-0.043); African Americans had the highest prevalence (42%), followed by Caucasians (27%) and Asians (24%) ( Table 2 ). African Americans were also found to have the highest rate of congestive heart failure (CHF) (19%; ES = 0.19; 95% CI, 0.03-0.35), obesity (21%; ES = 0.19; 95% CI, 0.04-0.36), and weight loss (12%; ES = 0.25; 95% CI, 0.09-0.41). The highest rate of renal failure was also found in African Americans (41%; ES = 0.24; 95% CI, 0.08-0.40) compared to Caucasians (29%) and Asians (26%).
Gender and Payer
Males had a significantly longer LOS compared to females (10.2 ± 24.6 days vs 6.4 ± 7.8 days; ES = 0.19; 95% CI, 0.05-0.33). However, no detectable differences were found with respect to complication rate (ES = 0.09; 95% CI, −0.05 to 0.23), mortality (ES = 0.09; 95% CI, −0.05 to 0.23), and readmission rate (ES = 0.04; 95% CI, −0.10 to 0.18). With regard to payer groups (private insurance, Medicaid, Medicare, self-pay, and other), the only significant difference found was between privately insured patients and the other payer group, which had the shortest and longest LOS, respectively (5.1 ± 5.1 days vs 14.6 ± 38.4 days; ES = 0.46; 95% CI, 0.15-0.78). There were no significant differences found between payer groups with respect to mortality, complications, or readmissions. 
Comorbidities
Specific Diagnoses
Facial nerve involvement (palsy or paresis) was documented in 15.5% of patients and was associated with a significantly longer mean LOS of 12.9 ± 19.6 days (ES = 0.21; 95% CI, 0.03-0.41) compared to the remainder of the patients. Differences in the mortality rate compared to patients without facial nerve involvement were not 
Discussion
Malignant otitis externa is a complex and potentially lifethreatening infection with many associated complications and comorbidities. This study provides insight into key prognostic indicators of this disease process and provides nationwide data that individual institutions can use to determine treatment benchmarks. Prior studies looking at MOE have been able to demonstrate that certain characteristics, including elderly patients, patients with diabetes, and those with fungal infections, affect morbidity and mortality rates compared to other patients with MOE. 8, 9, 13 This current study offers a further insight into key factors that contribute to longer LOS and/or were associated with hospitalacquired complications that have not been previously described by other studies.
Associations With Aging and Comorbidities
We found that increasing age has significant impact on disease incidence and mortality. Several hypotheses have been proposed for the physiologic connection between advanced age and MOE, including decreased epithelial migration of the ear canal and microvascular disease inhibiting a proper immune response. 15 Advanced age has been linked to comorbidities, including diabetes, which is known to be associated with impaired immune response and microvascular disease. 20 The first study of MOE in 1968 by Chandler 1 believed it to be a disease exclusive to diabetics based on a limited number of cases. Recent studies have varie,d with reported incidence of diabetes anywhere from 5% to 90%. [16] [17] [18] In our study, 64.4% had diabetes, and patients that had complications related to diabetes were found to have a significantly increased LOS compared to those without chronic complications. Our findings agree with a previous study showing a more severe type of MOE is associated with a history of diabetic vascular complications.
19 A1C levels have also been correlated with recovery time, indicating the importance of tight glycemic control during treatment. 20 Our data support the presence of the progressive complications of diabetes portends worst outcomes from MOE. We recommend physicians to include MOE on their differential for patients with diabetes, particularly poorly controlled diabetes, or its associated chronic complications (retinopathy, vasculopathy, etc) when these patients present with otalgia or otitis externa.
Weight loss was also associated with significantly worse outcomes, including increased LOS, complications, and mortality. Weight loss is comprised of diagnoses related to clinically significant low body weight and malnutrition and ultimately impaired immune response as a result, which has been associated with increased inpatient mortality. 12, 21, 22 This is likely present in numerous immunocompromised states in which MOE is known to occur. Patient frailty is a research topic of increasing interest, and further research looking at frailty index scores for MOE should be considered. The other comorbidities that had significantly impacted LOS, ICU admission, complications, and mortality were CHF and coagulopathy. These 2 comorbidity categories are most likely influenced by these patients being older and having several other comorbidities. In addition, other diagnoses such as immunosuppressive disorders that may be associated with MOE were not well defined using ICD-9-CM classification system.
Cranial Nerve Involvement
With regard to facial nerve involvement, we found no statistically significant increase in mortality in patients, whereas other studies have found facial nerve involvement significantly associated with higher mortality. 23, 24 We found an overall mortality rate of 2.5% (20) in our cohort of 786 patients, though this only included mortalities during initial inpatient admission. Studies following patients over a longer term have found mortality rates of 3.6% to 14%. 23, 25 A significantly higher mortality rates in patients with involvement of the facial nerve may have been found if follow-up data over the long-term were available. Lower cranial neuropathies have been shown to lead to worse outcomes and higher rates of mortality. 9 Unfortunately, the database does not provide specific information regarding other lower cranial neuropathies.
Differences in Race and Gender
We also found that males had higher incidences and significantly increased LOS, a finding in other studies of MOE as well.
9,26-28 However, gender was not significant in complication, mortality, and readmission rates. It has been suggested that male gender may be associated with a more severe form of MOE. 9 Another finding of our study was that race was a significant factor in patient outcomes, particularly for African Americans. This group also had a significantly higher incidence rate of CHF, obesity, renal failure, and diabetes without chronic complications as well as a 2.4-fold greater incidence of MOE compared to Caucasians. Although the presence of comorbidities likely explains increased incidence, there were no significant differences among racial groups in outcomes except readmission rate and ICU admission rate that should be considered when treating this population.
Surgical Intervention
There is a growing trend toward surgical intervention in severe cases of MOE. [29] [30] [31] [32] The surgical patients in our study had a significantly longer LOS but no significant difference in mortality. The most likely explanation for the increased LOS in this population is that patients requiring surgery may have more severe disease requiring longer hospitalizations. While MOE is not traditionally a surgical disease, surgery may be considered to obtain adequate cultures, debride necrotic tissue, or rule out an underlying malignancy. Surgery has traditionally been utilized if medical management is failing. Further studies are needed with individual patient-level data to better determine the role of surgery in MOE.
Limitations
The limitations of this study are similar to other large database studies in that patient-level data cannot be accessed. The UHC database does not allow us to access physical examination findings, laboratory data, and radiographic imaging. Our study is limited by the analysis of summary data from the UHC database that precludes us from performing multivariate analysis. Although we were unable to extract these data, we were still able to draw meaningful conclusions concerning MOE. Coding practices employed by institutions may vary based on institutional size creating another potential bias, which could change the capture rate for diagnoses and complications. Further ICD-9-CM coding is performed by nonclinicians who may incorrectly interpret findings in the chart, introducing error and bias into the data. However, the UHC database has been found to have a high level of concordance with patient-level institutional charts. 33 Other limitations include that the data only address the inpatient treatment of MOE and cannot address those patients managed on an outpatient basis. Further, we were unable to determine which patients received the diagnosis of MOE by an otolaryngologist or which patients had specific imaging modalities, including technetium or gallium scan, to ascertain the diagnosis.
Conclusion
This study of MOE from a large national database demonstrates the significant negative outcomes in patients that are elderly, have diabetes with chronic complications, and have other significant comorbidities. These findings should help providers who treat and manage patients with MOE with educating patients on duration of hospitalization, risk of complications, and mortality rates. Additionally, it serves as a nationwide synopsis of patient outcomes that can be used by hospital systems to develop treatment benchmarks and corroborates other national studies key findings.
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